Unfortunately, a study published in JAMA, found that the use of certain diabetes or weight loss medications (i.e., GLP-1 agonists such as Ozempic, Mounjaro, Wegovy, or Rybelsus) may be associated with an increased risk of developing stomach paralysis or gastroparesis
ANSM, GLP-1 analogous prescribing conditions, June 2025 : expansion to general practitioners
Ozempic and Zepbound are FDA-approved brand-name products Insurance: not required, according to VivioMD HSA/FSA: accepted as a payment method, according to VivioMD
Patients often ask about the differences among Ozempic, Wegovy, Rybelsus, and Mounjaro, which differ in formulation, FDA-approved use, dosing, effectiveness, and administration
Wegovys list price is $1,340.02 per month
Continue taking your medication as prescribed unless advised otherwise by your healthcare team